GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thor Medical ASA (OSTO:NANOo) » Definitions » EV-to-FCF

Thor Medical ASA (OSTO:NANOO) EV-to-FCF : (As of May. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Thor Medical ASA EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Thor Medical ASA's Enterprise Value is kr195.53 Mil. Thor Medical ASA's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.00 Mil. Therefore, Thor Medical ASA's EV-to-FCF for today is .

The historical rank and industry rank for Thor Medical ASA's EV-to-FCF or its related term are showing as below:

OSTO:NANOo' s EV-to-FCF Range Over the Past 10 Years
Min: -23.19   Med: -2.13   Max: 1.79
Current: -3.14

During the past 13 years, the highest EV-to-FCF of Thor Medical ASA was 1.79. The lowest was -23.19. And the median was -2.13.

OSTO:NANOo's EV-to-FCF is ranked worse than
100% of 390 companies
in the Biotechnology industry
Industry Median: 6.305 vs OSTO:NANOo: -3.14

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-14), Thor Medical ASA's stock price is kr1.95. Thor Medical ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.000. Therefore, Thor Medical ASA's PE Ratio for today is N/A.


Thor Medical ASA EV-to-FCF Historical Data

The historical data trend for Thor Medical ASA's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thor Medical ASA EV-to-FCF Chart

Thor Medical ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.00 -2.41 -4.93 -0.10 -4.06

Thor Medical ASA Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.31 -0.01 -0.10 - -4.06

Competitive Comparison of Thor Medical ASA's EV-to-FCF

For the Biotechnology subindustry, Thor Medical ASA's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thor Medical ASA's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thor Medical ASA's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Thor Medical ASA's EV-to-FCF falls into.



Thor Medical ASA EV-to-FCF Calculation

Thor Medical ASA's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=195.525/0
=

Thor Medical ASA's current Enterprise Value is kr195.53 Mil.
Thor Medical ASA's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Thor Medical ASA  (OSTO:NANOo) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Thor Medical ASA's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.95/0.000
=N/A

Thor Medical ASA's share price for today is kr1.95.
Thor Medical ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Thor Medical ASA EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Thor Medical ASA's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Thor Medical ASA (OSTO:NANOO) Business Description

Traded in Other Exchanges
Address
Kjelsasveien 168 B, Oslo, NOR, 0884
Nordic Nanovector ASA is a biopharmaceutical company. It is engaged in the development and commercialization of targeted therapeutics to improve the lives of patients with haematological cancers, such as non-Hodgkin lymphoma and leukaemia. The company's main clinical stage product is Betalutin.

Thor Medical ASA (OSTO:NANOO) Headlines

No Headlines